The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Functional recovery in parkinsonian monkeys treated with GDNF
Abstract
Parkinson's disease results from the progressive degeneration of dopamine neurons that innervate the striatum. In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons. Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally in rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, growth factor–mediated prevention of neuronal loss in transection models has predicted protection from disease-specific mechanisms in other models22–25.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [24]
Citations
Cites
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Self-citationProtection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
A consideration of neural counting methods
Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540
Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Self-citationGDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Self-citationBankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Flagged first, then by citations
Research works printed but not linked: 2
- Jellinger, K. Adv. Neurol. 45, 1–18 (1986).
- Hornykiewicz, O. & Kish, S. J. Adv. Neurol. 45, 19–34 (1986).
Cited by
Sorted by citations
Items 101–200 of 946
Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse
Messer, C. J., Eisch, A. J., Carlezon, W. A., Whisler, K., Shen, L., Wolf, D. H., Westphal, H., Collins, F., Russell, D., & Nestler, E. J. (2000) · Neuron · doi:10.1016/s0896-6273(00)81154-x · Cited by 168
Self-citationTonra, J. R. (1999) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19990515/01)45:4/5 · Cited by 38
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. L. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 171
Rosenblad, C., Kirik, D., & Björklund, A. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7296 · Cited by 161
Granholm, A., Reyland, M. E., Albeck, D. S., Sanders, L., Gerhardt, G. A., Hoernig, G. R., Shen, L., Westphal, H., & Hoffer, B. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03182.2000 · Cited by 160
Self-citationTreatment of Parkinson’s Disease with Trophic Factors
Peterson, A. L., & Nutt, J. G. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.02.003 · Cited by 159
Ebert, A. D., Beres, A. J., Barber, A. E., & Svendsen, C. N. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.09.022 · Cited by 161
Tseng, J., Baetge, E. E., Zurn, A. D., & Aebischer, P. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-01-00325.1997 · Cited by 158
TGF-β and the regulation of neuron survival and death
KRIEGLSTEIN, K. G., Strelau, J., Schober, A., Sullivan, A. M., & Unsicker, K. (2002) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00077-8 · Cited by 158
Oo, T. F., & Burke, R. E. (1997) · Developmental Brain Research · doi:10.1016/s0165-3806(96)00173-3 · Cited by 158
Iannotti, C. A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00188-2 · Cited by 157
Hamilton, J. F., Morrison, P. F., Chen, M. Y., Harvey-White, J. D., Sánchez‐Pernaute, R., PHILLIPS, H. S., Oldfield, E. H., & Bankiewicz, K. S. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7571 · Cited by 158
Evaluation of animal models of Parkinson's disease for neuroprotective strategies
Emborg, M. E. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.08.004 · Cited by 160
Lin, C., Hsieh, H.-Y., Chen, C., Wu, S.-R., Tsai, C.-H., Huang, C.-Y., Hua, M., Wei, K., Yeh, C., & Liu, H.-L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.052 · Cited by 156
Neurotrophic factor therapy for Parkinson’s disease
Rangasamy, S. B., Soderstrom, K. E., Bakay, R. A. E., & Kordower, J. H. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84013-0 · Cited by 155
Sun, M., Kong, L., Wang, X., Lu, X.-G., Gao, Q., & Geller, A. I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.05.072 · Cited by 154
Rosenblad, C., Martı́nez-Serrano, A., & Björklund, A. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00269-8 · Cited by 152
Expression and regulation of GFRα3, a glial cell line-derived neurotrophic factor family receptor
Naveilhan, P., Baudet, C., Mikaels, Å., Shen, L., Westphal, H., & Ernfors, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1295 · Cited by 151
Extrastriatal dopaminergic circuits of the basal ganglia
Rommelfanger, K. S. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00139 · Cited by 166
The Total Synthesis of (±)-Merrilactone A
Birman, V. B., & Danishefsky, S. J. (2002) · Journal of the American Chemical Society · doi:10.1021/ja012495d · Cited by 150
CASS, W. A., SMITH, M. P., & PETERS, L. E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.023 · Cited by 149
Self-citationIntraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects
Ai, Y., Markesbery, W. R., Zhang, Z., Grondin, R., Elseberry, D., Gerhardt, G. A., & Gash, D. M. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10689 · Cited by 149
Self-citationZhao, Y., Haney, M. J., Gupta, R., Bohnsack, J. P., He, Z., Kabanov, A. V., & Batrakova, E. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106867 · Cited by 144
RetractedMetallothionein 1: A New Spotlight on Inflammatory Diseases
Dai, H., Wang, L., Li, L., Huang, Z. W., & Ye, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739918 · Cited by 143
The Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 145
Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia
Mena, M. A., & de Yébenes, J. G. (2008) · The Neuroscientist · doi:10.1177/1073858408322839 · Cited by 141
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverrı́a, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 146
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease
Voutilainen, M. H., Bäck, S., Peränen, J., Lindholm, P., Raasmaja, A., Männistö, P. T., Saarma, M., & Tuominen, R. K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.013 · Cited by 138
Zhang, Z., Miyoshi, Y., Lapchak, P. A., Collins, F., Hilt, D. C., LeBel, C. P., Kryscio, R. J., & Gash, D. M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36963-0 · Cited by 138
Self-citationWilson, M. T., & Snow, D. M. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20000828)424:3 · Cited by 73
Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates
Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S., McCormack, A. L., Kim, A., Tyndale, R. F., Langston, J. W., & Monte, D. A. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04078.x · Cited by 137
Grondin, R., Cass, W. A., Zhang, Z., Stanford, J. A., Gash, D. M., & Gerhardt, G. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01974.2003 · Cited by 134
Self-citationGrondin, R., & Gash, D. M. (1998) · Journal of Neurology · doi:10.1007/pl00007744 · Cited by 134
Self-citationHisaoka, K., Nishida, A., Koda, T., Miyata, M., Zensho, H., Morinobu, S., Ohta, M., & Yamawaki, S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00531.x · Cited by 133
Eigenbrot, C. W., & Gerber, N. C. (1997) · Nature Structural Biology · doi:10.1038/nsb0697-435 · Cited by 133
Protection of Visual Functions by Human Neural Progenitors in a Rat Model of Retinal Disease
Gamm, D. M., Wang, S., Lü, B., Girman, S., Holmes, T. M., Bischoff, N., Shearer, R. L., Sauvé, Y., Capowski, E. E., Svendsen, C. N., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000338 · Cited by 135
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis
Kearns, C. M., Cass, W. A., Smoot, M. K., Kryscio, R. J., & Gash, D. M. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07111.1997 · Cited by 131
Self-citationTrophic Factor Gene Therapy for Parkinson's Disease
Kordower, J. H., & Björklund, A. (2013) · Movement Disorders · doi:10.1002/mds.25344 · Cited by 129
Smith, M. P., Fletcher, A. M., Yurek, D. M., & Cass, W. A. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9048-4 · Cited by 129
Self-citationFernández‐Espejo, E., Montoro, R. J., Armengol, J. A., & López‐Barneo, J. (1998) · Neuron · doi:10.1016/s0896-6273(00)80449-3 · Cited by 129
Connor, B. J., Kozlowski, D. A., Schallert, T. J., Tillerson, J. L., Davidson, B. L., & Bohn, M. C. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301033 · Cited by 129
Sagi, Y., Mandel, S. A., Amit, T., & Youdim, M. B. H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.07.020 · Cited by 128
CHEN, Y., AI, Y., SLEVIN, J., MALEY, B., & GASH, D. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.010 · Cited by 126
Self-citationIn vitro study of GDNF release from biodegradable PLGA microspheres
Aubert‐Pouëssel, A., Venier‐Julienne, M., Clavreul, A., Sergent, M., Jollivet, C., Montero‐Menei, C. N., Garcion, E., Bibby, D. C., Meneï, P., & Benoît, J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.12.012 · Cited by 124
Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats
Pertusa, M., García‐Matas, S., Mammeri, H., Adell, A., Rodrigo, T., Mallet, J. J., Cristòfol, R. M., Sarkis, C., & Sanfeliu, C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.026 · Cited by 123
Członkowska, A., Kurkowska‐Jastrzębska, I., Członkowski, A., Peter, D., & Stefano, G. B. (2002) · PubMed · Cited by 123
Granulocyte‐colony stimulating factor is neuroprotective in a model of Parkinson's disease
Meuer, K., Pitzer, C., Teismann, P., Krüger, C., Göricke, B., Laage, R., Lingor, P., Peters, K., Schlachetzki, J. C. M., Kobayashi, K., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03727.x · Cited by 121
Mendez, I. M., Dagher, A., Hong, M. G. L., Hebb, A. O., Gaudet, P., Law, A., Weerasinghe, S. D. S., King, D., Desrosiers, J., Darvesh, S., et al. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.5.0863 · Cited by 121
Barnett, M. W., Fisher, C. E., Perona‐Wright, G., & Davies, J. A. (2002) · Journal of Cell Science · doi:10.1242/jcs.00114 · Cited by 119
Applications of Acupuncture Therapy in Modulating Plasticity of Central Nervous System
Xiao, L., Wang, X., Yang, Y., Yang, J., Cao, Y., Ma, S., Li, T., & Liu, C. (2017) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12724 · Cited by 121
Sautter, J., Tseng, J., Braguglia, D., Aebischer, P., Spenger, C., Seiler, R. W., Widmer, H. R., & Zurn, A. D. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6718 · Cited by 117
An Acid-Treatment Method for the Enhanced Detection of GDNF in Biological Samples
Okragly, A. J., & Haak‐Frendscho, M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6500 · Cited by 116
Fan, C., Ting, C.-Y., Lin, C., Chan, H., Chang, Y., Chen, Y., Liu, H.-L., & Yeh, C. (2016) · Scientific Reports · doi:10.1038/srep19579 · Cited by 119
Biomaterials for Brain Tissue Engineering
Pettikiriarachchi, J. T. S., Parish, C. L., Shoichet, M. S., Forsythe, J. S., & Nisbet, D. R. (2010) · Australian Journal of Chemistry · doi:10.1071/ch10159 · Cited by 115
Parkinson disease: etiology, pathogenesis and future of gene therapy
Shastry, B. S. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00254-1 · Cited by 115
Sanchez, B., Relova, J. L., Gallego, R., Batalla, I. B., & Pérez-Fernández, R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21878 · Cited by 113
Novel targeted therapies for Parkinson’s disease
Ntetsika, T., Papathoma, P.-E., & Markaki, I. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00279-2 · Cited by 120
The Role of Neurotrophic Factors in Psychostimulant-induced Behavioral and Neuronal Plasticity
Pierce, R. C., & Bari, A. (2001) · Reviews in the Neurosciences · doi:10.1515/revneuro.2001.12.2.95 · Cited by 111
Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease
Eberhardt, O. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00428-9 · Cited by 111
Glazner, G. W., Mu, X., & Springer, J. E. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980202)391:1 · Cited by 110
Luquín, M. R., Montoro, R. J., Guillén, J., Saldise, L., Insausti, R., Río, J. D., & López‐Barneo, J. (1999) · Neuron · doi:10.1016/s0896-6273(00)80733-3 · Cited by 109
Vitamin D Receptor Gene as a Candidate Gene for Parkinson Disease
Butler, M. W., Burt, A., Edwards, T. L., Zuchner, S. L., Scott, W. K., Martin, E. R., Vance, J. M., & Wang, L. (2011) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2010.00631.x · Cited by 108
Tuszynski, M. H., & Blesch, A. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46028-7 · Cited by 108
Salvatore, M. F., Zhang, J., Large, D. M., Wilson, P. E., Gash, C. R., Thomas, T. C., Haycock, J. W., Bing, G., Stanford, J. A., Gash, D. M., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02496.x · Cited by 108
Self-citationHovland, D. N., Boyd, R. B., Butt, M. T., Engelhardt, J. A., Moxness, M. S., Ma, M. H., Emery, M. G., Ernst, N. B., Reed, R. P., Zeller, J. R., et al. (2007) · Toxicologic Pathology · doi:10.1177/01926230701481899 · Cited by 108
Self-citationBoger, H., Middaugh, L. D., Huang, P., Zaman, V., SMITH, A., Hoffer, B. J., Tomac, A., & Granholm, A. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.06.006 · Cited by 108
Self-citationKozlowski, D. A., Connor, B. J., Tillerson, J. L., Schallert, T. J., & Bohn, M. C. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7463 · Cited by 108
Hebert, M. A., & Gerhardt, G. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36878-8 · Cited by 108
Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease
Migliore, M. M., Ortiz, R., Dye, S., Campbell, R. B., Amiji, M. M., & Waszczak, B. L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.019 · Cited by 107
GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro
Clarkson, E. D., Zawada, W. M., & Freed, C. R. (1997) · Cell and Tissue Research · doi:10.1007/s004410050867 · Cited by 107
Murray, T. K., Whalley, K., Robinson, C. S., Ward, M., Hicks, C. A., Lodge, D., Vandergriff, J. L., Baumbarger, P. J., Siuda, E. R., Gates, M. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049445 · Cited by 107
Steiner, H., Blum, M., Kitai, S. T., & Fedi, P. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7163 · Cited by 106
RET Is Dispensable for Maintenance of Midbrain Dopaminergic Neurons in Adult Mice
Jain, S. R., Golden, J. P., Wozniak, D. F., Pehek, E. A., Johnson, E. M., & Milbrandt, J. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1876-06.2006 · Cited by 106
Biju, K. C., Zhou, Q., Li, G., Imam, S. Z., Roberts, J. L., Morgan, W. W., Clark, R. A., & Li, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.107 · Cited by 106
Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
Hou, L., Chen, W., Liu, X., Qiao, D., & Zhou, F.-M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00358 · Cited by 112
Oiwa, Y., Yoshimura, R., Nakai, K., & Itakura, T. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02934-7 · Cited by 105
Mínguez‐Castellanos, A., Sevilla, F. E., Hotton, G. R., Toledo‐Aral, J. J., Ortega-Moreno, A., Méndez‐Ferrer, S., Martín‐Linares, J. M., Katati, M. J., Mir, P., Villadiego, J., et al. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.106021 · Cited by 104
Granholm, A.-C., Mott, J. L., Bowenkamp, K. E., Eken, S., Henry, S., Hoffer, B. J., Lapchak, P. A., Palmer, M. R., van Horne, C. G., & Gerhardt, G. A. (1997) · Experimental Brain Research · doi:10.1007/pl00005741 · Cited by 104
Self-citationStem cells in the treatment of Parkinson’s disease
Arenas, E. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00772-9 · Cited by 104
Cunningham, L. A., & Su, C. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7877 · Cited by 103
Jollivet, C., Aubert‐Pouëssel, A., Clavreul, A., Venier‐Julienne, M., Remy, S., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00601-x · Cited by 103
Eslamboli, A., Cummings, R. M., Ridley, R. M., Baker, H. F., Muzyczka, N., Bürger, C., Mandel, R. J., Kirik, D., & Annett, L. E. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.007 · Cited by 103
Samiotaki, G., Acosta, C., Wang, S., & Konofagou, E. E. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.236 · Cited by 102
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Jasutkar, H. G., Oh, S. E., & Mouradian, M. M. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000133 · Cited by 104
Neural stem cells in Parkinson’s disease: a role for neurogenesis defects in onset and progression
Grand, J. N. L., González-Cano, L., Pavlou, M. A. S., & Schwamborn, J. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1774-1 · Cited by 105
Autotransplantation of Human Carotid Body Cell Aggregates for Treatment of Parkinson’s Disease
Arjona, V., Mínguez‐Castellanos, A., Montoro, R. J., Ortega, A., Sevilla, F. E., Toledo‐Aral, J. J., Pardal, R., Méndez‐Ferrer, S., Martín, J. M., Pérez-Garcı́a, M., et al. (2003) · Neurosurgery · doi:10.1227/01.neu.0000073315.88827.72 · Cited by 100
de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00010 · Cited by 99
Cass, W. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08132.1996 · Cited by 99
Self-citationMesenchymal stem cells and neuroregeneration in Parkinson's disease
Glavaski‐Joksimovic, A., & Bohn, M. C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.016 · Cited by 99
The mitochondrial kinase PINK 1: functions beyond mitophagy
Voigt, A., Berlemann, L. A., & Winklhofer, K. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13655 · Cited by 100
Gerhardt, G. A., Cass, W. A., Huettl, P. F., Brock, S., Zhang, Z., & Gash, D. M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01244-x · Cited by 98
Self-citationTrophic factor distribution predicts functional recovery in parkinsonian monkeys
Gash, D. M., Zhang, Z., Ai, Y., Grondin, R., Coffey, R. J., & Gerhardt, G. A. (2005) · Annals of Neurology · doi:10.1002/ana.20549 · Cited by 97
Self-citationGene therapy with AAV 2‐ CDNF provides functional benefits in a rat model of P arkinson's disease
Bäck, S., Peränen, J., Galli, E., Lindholm, P., Lonka‐Nevalaita, L., Tamminen, T., Voutilainen, M. H., Raasmaja, A., Saarma, M., Männistö, P. T., et al. (2013) · Brain and Behavior · doi:10.1002/brb3.117 · Cited by 97
Lapchak, P. A., Araujo, D. M., Hilt, D. C., Sheng, J., & Jiao, S. (1997) · Brain Research · doi:10.1016/s0006-8993(97)01100-1 · Cited by 97
Self-citationIannotti, C. A., PINGZHANG, Y., Shields, C. L., HAN, Y., BURKE, D., & Xu, X. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.033 · Cited by 96
Drinkut, A., Tereshchenko, Y., Schulz, J. B., Bähr, M., & Kügler, S. (2011) · Molecular Therapy · doi:10.1038/mt.2011.249 · Cited by 95
Nerve Growth Factor Gene Therapy in Alzheimer Disease
Tuszynski, M. H. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318068d6d2 · Cited by 99
Hidalgo‐Figueroa, M., Bonilla, S., Gutiérrez, F., Pascual, A., & López‐Barneo, J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2693-11.2012 · Cited by 95
Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys
Zhang, Z., Andersen, A. H., Avison, M. J., Gerhardt, G. A., & Gash, D. M. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02243-x · Cited by 94
Self-citation
Metadata
- Authors
- Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., & Gerhard, G. A.
- Affiliations
- University of Kentucky (US)
- Venue
- Nature
- Published
- 1996-03
- Volume
- 380
- Issue
- 6571
- Pages
- 252-255
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971258758
- Cited by
- 955
- References
- 22
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 20 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 20 · 2017: 13 · 2016: 21 · 2015: 27 · 2014: 24 · 2013: 30 · 2012: 27
- FWCI
- 51.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, glial cell line-derived neurotrophic factor, MPTP-induced parkinsonism, rhesus monkeys, dopaminergic neurons, midbrain dopamine, globus pallidus, nigral neurons, bradykinesia, rigidity, postural instability, functional recovery, neuroprotection, neurotrophic therapy
- MeSH terms
- Animals, Dopamine, Female, Humans, Macaca mulatta, Mesencephalon, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Recombinant Proteins, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Glial Cell Line-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
